Integrative Multi-omics and Machine Learning Reveal the Therapeutic Mechanisms of Juanyu-Xiaozhi Formula in Metabolic Dysfunction-associated Steatotic Liver Disease and Hepatic Fibrosis via the AP-1/PPARγ/SCD1 Axis (IMAGE)
Caption
This study demonstrates the therapeutic efficacy of JYXZF in a MASH diet-induced rat model and elucidates its lipid-lowering and antifibrotic mechanisms through an integrated strategy combining multi-omics analyses, machine learning-based target prioritization, and functional validation experiments. We further show that JYXZF reduces hepatic lipid accumulation and collagen deposition by attenuating AP-1-mediated transcriptional activation of PPARγ and its downstream effector SCD1. Regulation of this AP-1/PPARγ/SCD1 pathway may contribute to the protective effects of JYXZF against MASLD/MASH progression. These findings not only clarify the mechanisms underlying the effects of JYXZF but also provide a basis for developing multi-target therapeutic approaches for metabolic liver diseases based on TCM.
Credit
Huabao Liu, Yang Yang
Usage Restrictions
Credit must be given to the creator. Only noncommercial uses of the work are permitted.
License
CC BY-NC